Table 5.
Best classifiers in patients with or without SRL presurgical treatment, extrasellar growth, sinus invasion, biological sex and GNAS mutational status.
| Fragmenting condition | Evaluated comparison | Fragmented population Na | Best panel of classifiers | ACC | p-value |
|---|---|---|---|---|---|
| A. SRL presurgical treatement | CR + PR vs NR | No (9 vs 7) | PLAGL1 + PEBP1 + E-cadherin | 88.89% | 0.003 |
| Yes (33 vs 19) | SSTR5 + DRD2 long isoform + E-cadherin | 70.65% | 0.001 | ||
| CR vs NR | No (6 vs 7) | Age + SSTR2 + E-cadherin | 100.00% | 5.83E−04 | |
| Yes (20 vs 19) | PLAGL1 + IN1GHRL + E-cadherin | 76.97% | 9.43E−04 | ||
| PR vs NR | No (3 vs 7) | Not found | – | – | |
| Yes (13 vs 19) | SSTR5 + PEBP1 | 74.29% | 0.003 | ||
| CR vs PR | No (6 vs 3) | SSTR2 + E-cadherin | 100% | 0.012 | |
| Yes (20 vs 13) | PEBP1 + IN1GHRL | 76.82% | 4.02E−04 | ||
| B. Extrasellar growth | CR + PR vs NR | No (18 vs 1) | Not found | – | – |
| Yes (20 vs 19) | GHRL | 71.32% | 0.005 | ||
| CR vs NR | No (12 vs 1) | Not found | – | – | |
| Yes (11 vs 19) | Not found | – | – | ||
| PR vs NR | No (6 vs 1) | Not found | – | – | |
| Yes (9 vs 19) | Not found | – | – | ||
| CR vs PR | No (12 vs 6) | SSTR5 + PEBP1 | 87.50% | 0.004 | |
| Yes (11 vs 9) | SSTR5 + IN1GHRL + E-cadherin | 79.80% | 0.012 | ||
| C. Sinus Invasion | CR + PR vs NR | No (26 vs 7) | Not found | – | – |
| Yes (12 vs 10) | AIP | 77.50% | 0.015 | ||
| CR vs NR | No (18 vs 7) | SSTR2 + ARRB1 + KLK10 | 81.75% | 0.007 | |
| Yes (5 vs 10) | PEBP1 + AIP + IN1GHRL | 85.00% | 0.017 | ||
| PR vs NR | No (8 vs 7) | Ki-67 + IN1GHRL | 85.71% | 0.007 | |
| Yes (7 vs 10) | Not found | – | – | ||
| CR vs PR | No (18 vs 8) | SSTR2 + IN1GHRL + KLK10 | 86.61% | 0.009 | |
| Yes (5 vs 7) | Not found | – | – | ||
| D. Gender | CR + PR vs NR | Female (25 vs 10) | PEBP1 + GHRL | 73.78% | 0.007 |
| Male (18 vs 16) | Age + E-cadherin | 80.83% | 0.001 | ||
| CR vs NR | Female (14 vs 10) | PEBP1 + E-cadherin + AIP | 79.76% | 0.005 | |
| Male (12 vs 16) | Age + PLAGL1 + E-cadherin | 85.45% | 4.91E−04 | ||
| PR vs NR | Female (11 vs 10) | Not found | – | – | |
| Male (6 vs 16) | SSTR2 + PLAGL1 + GHRL/ARRB1 | 85.35% | 0.003 | ||
| CR vs PR | Female (14 vs 11) | SSTR2 + PEBP1 | 74.68% | 0.016 | |
| Male (12 vs 6) | DRD2 short and long isoform + E-cadherin | 80.00% | 0.018 | ||
| E. GNAS mutational status | CR + PR vs NR | WT (19 vs 14) | SSTR2 + DRD2 long isoform + ARRB1 | 77.07% | 0.003 |
| Mutated (10 vs 5) | Not found | – | – | ||
| CR vs NR | WT (10 vs 14) | Not found | – | – | |
| Mutated (5 vs 5) | PLAGL1 + E-cadherin + Ki-67 | 90.00% | 0.024 | ||
| PR vs NR | WT (9 vs 14) | SSTR5 + ARRB1 | 72.22% | 0.014 | |
| Mutated (5 vs 5) | Not found | – | – | ||
| CR vs PR | WT (10 vs 9) | PEBP1 + E-cadherin | 84.44% | 0.004 | |
| Mutated (5 vs 5) | Not found | – | – | ||
| F. Hypointense T2 signaling | CR + PR vs NR | NO HYPO (23 vs 15) | SSTR3 + ARRB1 + AIP | 74.18% | 0.008 |
| HYPO (14 vs 8) | DRD2 short isoform + Ki-67 | 75.00% | 0.040 | ||
| CR vs NR | NO HYPO (13 vs 15) | SSTR3 + SSTR2 + Ki-67 | 88.46% | 8,75E−05 | |
| HYPO (9 vs 8) | E-cadherin | 87.50% | 0.003 | ||
| PR vs NR | NO HYPO (10 vs 15) | Age + DRD2 short isoform + PEBP1 | 76.79% | 0.022 | |
| HYPO (5 vs 8) | Not found | – | – | ||
| CR vs PR | NO HYPO (10 vs 9) | DRD2 short isoform + KLK10 | 85.04% | 0.001 | |
| HYPO (5 vs 5) | Not found | – | – |
For each subgroup, the best panel/s of classifiers (with accuracy higher than the maximal one achieved by the classifiers using the whole cohort without fragmentation) in each comparison are shown. aThe third column refers to the condition in the first column. ACC Accuracy.